Cheng Wang

10PUBLICATIONS
26CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Dec 18, 2025
Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers.

Mengyao Xu, Syem K Barakzai, Raj Kumar

|Nov 24, 2025
Rete Ovarii Epithelial Cells as an Unappreciated Cell of Origin for Pelvic and Ovarian High-Grade Serous Carcinoma.

Cheng Wang, Peichao Chen, Xingeng Zhao

|Apr 10, 2025
Hyperactivated YAP1 is essential for sustainable progression of renal clear cell carcinoma.

Xiangmin Lv, Jiyuan Liu, Kazi Islam

|Mar 25, 2025
Targeting the disrupted Hippo signaling to prevent neoplastic renal epithelial cell immune evasion.

Xiangmin Lv, Jiyuan Liu, Jinpeng Ruan

|Sep 13, 2024
HPV-YAP1 oncogenic alliance drives malignant transformation of fallopian tube epithelial cells.

Chunbo He, Xiangmin Lv, Jiyuan Liu

|Sep 15, 2023
Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment.

Yufeng Wang, David L Drum, Ruochuan Sun

Pageof 2

Frequent Collaborators

4 joint publications

Davie Shi

4 joint publications

Jiyuan Liu

3 joint publications

Oladapo Yeku

3 joint publications

John S Davis